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Galanin inhibits hair follicle growth
Holub et al. present the first evidence that human hair follicles 
(HFs) are both a source and a functionally relevant target of 
galanin. Galanin-like immunoreactivity was detected in the 
outer root sheath (ORS) and inner root sheath. Additionally, 
galanin mRNA was detected in ORS keratinocytes and all HF 
samples tested. Galanin receptor transcripts (GalR2, GalR3) 
were also detected in selected samples. Galanin reduced prolif-
eration of hair matrix keratinocytes in situ compared with vehi-
cle-treated controls, shortened the hair growth phase (anagen) in 
vitro and reduced hair shaft elongation. This was accompanied 
by the premature development of a catagen-like morphology of 
galanin-treated HFs. The current data suggest that galanin can 
serve as a new lead compound in the search for novel agents 
that reduce or prevent unwanted hair growth. Br J Dermatol 
2012; 167: 10–16
Narrowband UVB, oral cholecalciferol and 
vitamin D balance
Ala-Houhala et al. compared the effects of a short course of nar-
rowband ultraviolet B (NB-UVB) and oral vitamin D substitution 
in healthy subjects in winter. Healthy participants with 25(OH)
D below 75 nmol L–1 were randomly given either 12 NB-UVB 
exposures or 20 mg of oral cholecalciferol daily for 4 weeks. 
The baseline serum 25(OH)D concentrations were 52.9 ± 
10.4 (mean ± SD) in the 33 NB-UVB-treated and 53.5 ± 12.7 
nmol L–1 in the 30 oral vitamin D-treated subjects. The mean 
increase in serum 25(OH)D was 41.0 nmol L–1 in the NB-UVB 
group and 20.2 nmol L–1 in the cholecalciferol group. The dif-
ference between the two treatments was significant at 2 weeks 
(P = 0.033) and at 4 weeks (P < 0.001). It is concluded that a 
short NB-UVB course is an effective way to improve vitamin D 
balance in winter and the response is still evident 2 months after 
the course. Br J Dermatol 2012; 167: 160–64
Efficacy and safety of certolizumab pegol  
in plaque psoriasis
Reich et al. report results of a randomized, placebo-controlled 
trial of 176 patients with moderate to severe psoriasis who 
received placebo or certolizumab pegol (CZP) 400 mg at week 
0 followed by placebo or CZP (200 or 400 mg) every other 
week until week 10. A re-treatment extension study was con-
ducted in 71 CZP PASI 75 responders who relapsed during a 
12- to 24-week observation period without treatment. PASI 75 
was achieved by 75%, 83% and 7% of patients in the CZP 200 
mg, CZP 400 mg and placebo groups, respectively (P < 0.001 
for both treatment arms vs. placebo). The efficacy observed dur-
ing the re-treatment period was similar to that observed during 
the first treatment period. These phase II results support the con-
tinued clinical programme for development of CZP in psoriasis. 
Br J Dermatol 2012; 167: 180–90
Etanercept acutely suppresses the IL-20 
cytokine subfamily
Wang et al. investigated early biochemical and cellular effects 
of etanercept on psoriasis lesions prior to substantial clinical 
improvement. By 1 week, etanercept suppressed gene expres-
sion of the interleukin (IL)-20 subfamily of cytokines (IL-19, 
IL-20, IL-24), and suppression of other keratinocyte-derived 
products. Suppression of epidermal regenerative hyperpla-
sia occurred within 1–3 weeks. Th17 elements (IL-23p19, 
IL-12p40, IL-17A, IL-22) were suppressed by 3–4 weeks. These 
findings would support that epidermal activation is a very early 
target of etanercept. As many of these keratinocyte markers are 
stimulated by tumour necrosis factor (TNF)-α, their rapid down-
regulation is likely to reflect etanercept’s antagonism of TNF-α. 
Additionally, decreased epidermal hyperplasia might result spe-
cifically from acute suppression of the IL-20 subfamily, which is 
also a likely consequence of etanercept’s antagonism of TNF-α. 
Thus, the IL-20 subfamily has potential importance in the patho-
genesis of psoriasis and therapeutic response to etanercept. Br J 
Dermatol 2012; 167: 92–102
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